The Evidence Pack: How GLP-1 Drugs Are Forcing Pension Funds to Recalculate Longevity Liabilities

For decades, the financial models underpinning the global retirement system have relied on a slow, predictable upward curve in human life expectancy. But the widespread adoption of GLP-1 receptor agonists—the class of drugs that includes Ozempic, Wegovy, and Zepbound—has introduced a sudden, positive disruption to that math. What began as a treatment for type 2 diabetes has evolved into a generational medical breakthrough that is demonstrably reducing cardiovascular mortality, forcing the $35 trillion global pension industry to confront what risk managers call an 'actuarial shock.'[1][3]

The evidence driving this financial recalculation is anchored in large-scale clinical data. The landmark SELECT trial, published in The New England Journal of Medicine, demonstrated that semaglutide reduced the risk of major adverse cardiovascular events—including heart attack, stroke, and cardiovascular death—by 20% in overweight or obese adults without diabetes. Because cardiovascular disease remains the leading cause of death globally, a 20% reduction in these events across a broad population translates directly into extended lifespans.[2]

For the medical community, this is a triumph. For the actuaries who calculate how much money pension funds need to hold in reserve, it is a complex puzzle. Defined benefit pension plans and lifetime annuity providers operate on a simple premise: they pool capital today to guarantee income for the remainder of a retiree's life. To ensure they do not run out of money, these institutions rely heavily on mortality improvement scales—highly sophisticated tables that predict exactly how long a specific demographic is likely to live.[1]

Historically, mortality improvements have been gradual, driven by incremental advances in public health, sanitation, and incremental medical care. The Society of Actuaries (SOA) typically updates its mortality scales annually, adjusting projections by fractions of a percent. However, the rapid uptake of GLP-1s represents a 'step-change' in population health. Early models suggest that broad adherence to these therapeutics could increase average life expectancy for treated populations by 1.5 to 2.5 years over the next decade.

In the world of pension finance, a single additional year of life expectancy carries an enormous price tag. Industry benchmarks dictate that for every extra year a retiree population lives, a pension fund's total liabilities increase by roughly 3% to 4%. When applied to a corporate pension plan managing $10 billion in assets, a two-year increase in life expectancy suddenly creates a $600 million to $800 million funding gap that the sponsoring company must eventually fill.[1]

This phenomenon is known as 'longevity risk'—the financial hazard that a population will live longer than expected, draining the capital reserves meant to support them. Morgan Stanley Research estimates that the widespread use of GLP-1s could reshape the demographic pyramid of developed nations, significantly increasing the ratio of retirees to working-age adults and expanding the total duration of retirement by up to 10%.

Corporate plan sponsors are not waiting for the final mortality tables to adapt. Many are accelerating 'Pension Risk Transfers' (PRTs), a financial maneuver where a company pays a specialized insurance company to take over its pension obligations. By offloading the plan to an insurer, the corporation removes the unpredictable longevity risk from its own balance sheet. The PRT market has seen record volume in recent years, driven in part by a desire to lock in current mortality assumptions before the full impact of GLP-1s is officially priced into the market.

Insurance companies, in turn, are deploying sophisticated hedging strategies to manage this incoming risk. Some are investing heavily in long-duration assets, such as infrastructure and private credit, which offer the steady, decades-long yields required to pay out extended annuities. Others are exploring 'longevity swaps,' complex derivative contracts where the risk of retirees living longer is traded with global reinsurers who have an appetite for uncorrelated demographic risks.[1]

Despite the clear medical data, actuaries face significant uncertainty in modeling the exact financial impact. The primary unknown is long-term patient adherence. Clinical trials show remarkable benefits, but real-world data indicates that a significant percentage of patients discontinue GLP-1 therapy within the first two years due to side effects, cost, or changing insurance coverage. If patients do not stay on the medication, the population-level mortality benefits—and the resulting pension liabilities—will be muted.[2][3]

Pricing and accessibility also complicate the actuarial models. Currently, the high out-of-pocket costs and restrictive insurance coverage for weight-loss indications mean that GLP-1 benefits are disproportionately concentrated among higher-income demographics. Because higher-income individuals already tend to have longer life expectancies and larger pension balances, the financial impact on pension funds may be amplified even if the drugs do not immediately reach the broader population.[3]

Furthermore, the secondary health benefits of GLP-1s are still being quantified. Emerging research suggests these medications may also reduce the incidence of sleep apnea, kidney disease, and certain obesity-related cancers. If these secondary benefits are confirmed in long-term studies, the upward revision to life expectancy could be even steeper than current cardiovascular models suggest, requiring further recalibration of global retirement assets.[2]

For individual retirees, this financial recalibration is entirely invisible, but the underlying reality is profoundly positive. The stress on the pension system is not the result of a market crash or economic mismanagement; it is the byproduct of a medical victory. People are living longer, healthier lives, free from the debilitating effects of cardiovascular disease that defined previous generations.[3]

Ultimately, the financial system is designed to adapt to demographic realities. While corporate sponsors and insurers will need to allocate more capital to cover extended lifespans, the broader economic benefits of a healthier senior population—including reduced acute healthcare costs and increased consumer spending during longer, active retirements—will likely offset the localized strain on pension ledgers.[3]

The actuarial shock triggered by GLP-1s is a testament to the speed at which medical innovation can rewrite the rules of global finance. As researchers continue to unlock the mechanisms of human longevity, the financial industry will continue to adjust its math, ensuring that the capital required to support a longer life is waiting when it is needed.[3]